Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Related MDT
Medtronics Reports FDA Approval Of Capsurefix Novus MRI Surescane 5076 Full-Body Scanners
Medtronic Announces Commencement of Pivotal Study of First Predictive Low Glucose Mgmt Technology for People with Diabetes
JPM Denies Report of Second Hack Attack (Fox Business)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Latest Ratings for MDT

DateFirmActionFromTo
Sep 2014NeedhamInitiates Coverage onBuy
Sep 2014Bank of AmericaReinstatesBuy
Sep 2014Sterne AgeeInitiates Coverage onNeutral

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional